News | August 12, 2024
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Subscribe To Our Newsletter & Stay Updated
